
L Catterton said the all-cash sale is expected to close in the fourth quarter of 2026 after accelerating growth at the wellness brand.
Procter & Gamble is set to buy supplement brand Thorne from L Catterton for $3.8 billion in cash under a definitive agreement expected to close in the fourth quarter of 2026, extending P&G's push into wellness as it looks to revive its weaker healthcare segment. CEO Shailesh Jejurikar said on CNBC that P&G was "really happy with the asset itself," and P&G shares rose as much as 1.2% after the announcement. L Catterton invested in Thorne in October 2023 and said it helped recruit leadership, expand marketing and commercial reach, invest in science and R&D, strengthen manufacturing and quality systems, and build technology and data infrastructure, including a proprietary AI wellness advisor. Founded in 1984, Thorne went public in 2021 at a valuation of about $525 million before L Catterton took it private in a $680 million deal in 2023; the agreed sale values the company at more than five times that level. Thorne surpassed $500 million in annual revenue in 2025 and is projected to reach $650 million in 2026, giving P&G a faster-growing supplements brand alongside Metamucil, Align Probiotic and New Chapter.